Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BIO-TECHNE Corp (TECH) vs Workday Inc (WDAY) Price & Performance

BIO-TECHNE CorpTrade
Workday IncTrade

Price performance (Past 24H)

Key statistics

BIO-TECHNE Corp vs Workday Inc — how do they compare? BIO-TECHNE Corp trades at $72.45 (market cap $11.36B), while Workday Inc trades at $189.64 (market cap $45.26B). The key difference: Workday Inc is far larger — about 4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Workday Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Workday Inc for 38 Days on average.

TECHWDAY
Market Cap
$11.36B$45.26B
Volume
5,390,3312,342,190
Sector
HealthTechnology
52-Week High
$72.61$245.67
52-Week Low
$43.31$112.55
Typical Hold Time
63 Days38 Days
Enterprise Value
$11.39B$45.63B
Dividend Yield
0.44%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.

The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.

Workday Inc

Workday (WDAY) trades at $184.26, down 1.23% on the day amid a broader tech selloff, with a bearish technical signal. The company shows strong revenue growth, reaching $8.45B in 2025, and has consistently beaten earnings estimates. Recent strategic moves include AI product launches and a 2.5% headcount reduction aimed at efficiency. Analyst consensus is bullish with a $202.92 price target, but negative net cash flow and high valuation ratios present risks.

The outlook for WDAY is mixed; strong fundamentals and AI integration offer growth potential, but high P/E of 38.25 and recent layoffs signal execution risks. Investors should weigh robust analyst support against valuation concerns and market volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TECH

No sentiment data available yet.

WDAY
100% Buy0% Sell
Avg holding period · 38 Days

Top news

Latest headlines on both assets

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →

About Workday Inc

Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.

Read more on WDAY →